STVN
VENTE TOTALE: 4 068 titres (~81 726,12 $ US)
- Insiders
- Santel Luciano, Magistretti Elisabetta
- Total bought
- —
- Total sold
- $81,726
- Last activity
- 2026-08-07
- Last synced
-
2026-08-13 10:04:48
Insider holdings as a share of total assets aren't available for this company.
Price (1 year)
Live chart from TradingView - pulls its own market data, independent of this site's database. Symbol resolution is best-effort (defaults to NASDAQ) since we don't store the exchange prefix.
Market snapshot
Signal
Neutral signal Scored 2026-08-10
STVN presents a moderate earnings catalyst (Q2 2026 beat + Liraglutide authorization in Europe) with a solid but confidence-discounted catalyst score of 70 (×0.75), yet the financial health composite of 60 is dragged…
The first sentence of the analysis written for STVN on 2026-08-10 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 29.0% | 27.4% | 31.3% | 32.5% | 31.4% | |
| Ebit Margin | 17.9% | 15.1% | 17.9% | 19.5% | 20.2% | |
| Ebitda Margin | 25.3% | 22.4% | 25.1% | 26.1% | 26.9% | |
| Operating Profit Margin | 16.1% | 14.6% | 18.5% | 19.6% | 19.2% | |
| Pretax Profit Margin | 15.9% | 14.5% | 17.5% | 19.1% | 19.6% | |
| Continuous Operations Profit Margin | 11.8% | 10.7% | 13.4% | 14.5% | 15.9% | |
| Net Profit Margin | 11.8% | 10.7% | 13.4% | 14.5% | 15.9% | |
| Bottom Line Profit Margin | 11.8% | 10.7% | 13.4% | 14.5% | 15.9% | |
| Current Ratio | 1.745 | 1.843 | 1.501 | 1.829 | 2.557 | |
| Quick Ratio | 1.244 | 1.330 | 1.056 | 1.368 | 2.118 | |
| Solvency Ratio | 0.208 | 0.215 | 0.239 | 0.313 | 0.330 | |
| Cash Ratio | 0.244 | 0.206 | 0.121 | 0.495 | 1.214 | |
| Price To Earnings Ratio | 34.947 | 48.936 | 44.890 | 31.664 | 37.250 | |
| Price To Earnings Growth Ratio | 2.505 | -2.243 | 11.896 | 0.000 | 0.417 | |
| Forward Price To Earnings Growth Ratio | 2.505 | -2.243 | 11.896 | 0.000 | 0.417 | |
| Price To Earnings Diluted Ratio | 34.947 | 48.936 | 44.890 | 31.664 | 37.250 | |
| Price To Earnings Diluted Growth Ratio | 2.505 | -2.243 | 11.896 | 0.000 | 0.417 | |
| Price To Book Ratio | 3.146 | 4.089 | 5.776 | 4.459 | 6.206 | |
| Price To Sales Ratio | 4.103 | 5.201 | 6.027 | 4.516 | 6.192 | |
| Price To Free Cash Flow Ratio | 218.045 | -36.388 | -19.427 | -31.772 | 259.270 | |
| Price To Operating Cash Flow Ratio | 17.013 | 36.860 | 62.175 | 42.998 | 39.193 | |
| Debt To Assets Ratio | 0.185 | 0.184 | 0.191 | 0.132 | 0.172 | |
| Debt To Equity Ratio | 0.317 | 0.305 | 0.350 | 0.219 | 0.290 | |
| Debt To Capital Ratio | 0.241 | 0.234 | 0.259 | 0.180 | 0.225 | |
| Long Term Debt To Capital Ratio | 0.185 | 0.179 | 0.176 | 0.118 | 0.179 | |
| Financial Leverage Ratio | 1.711 | 1.658 | 1.829 | 1.666 | 1.685 | |
| Working Capital Turnover Ratio | 2.843 | 3.199 | 3.236 | 2.160 | 2.398 | |
| Operating Cash Flow Ratio | 0.513 | 0.326 | 0.183 | 0.223 | 0.394 | |
| Operating Cash Flow Sales Ratio | 0.241 | 0.141 | 0.097 | 0.105 | 0.158 | |
| Free Cash Flow Operating Cash Flow Ratio | 0.078 | -1.013 | -3.200 | -1.353 | 0.151 | |
| Debt Service Coverage Ratio | 1.681 | 1.805 | 1.633 | 3.088 | 4.651 | |
| Interest Coverage Ratio | 8.396 | 23.476 | 46.517 | 48.890 | 33.304 | |
| Short Term Operating Cash Flow Coverage Ratio | 2.258 | 1.458 | 0.776 | 1.598 | 3.587 | |
| Operating Cash Flow Coverage Ratio | 0.584 | 0.363 | 0.265 | 0.473 | 0.546 | |
| Capital Expenditure Coverage Ratio | 1.085 | 0.497 | 0.238 | 0.425 | 1.178 | |
| Dividend Paid And Capex Coverage Ratio | 1.027 | 0.475 | 0.231 | 0.403 | 1.072 | |
| Dividend Payout Ratio | 0.105 | 0.123 | 0.098 | 0.095 | 0.083 | |
| Enterprise Value Multiple | 17.381 | 24.506 | 25.219 | 17.285 | 22.294 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 29.0% | ▲1.6% | ▼-1.3% |
| Ebit Margin | 17.8% | ▲2.7% | ▼-0.2% |
| Ebitda Margin | 25.3% | ▲2.9% | ▲0.2% |
| Operating Profit Margin | 16.1% | ▲1.5% | ▼-1.5% |
| Pretax Profit Margin | 15.9% | ▲1.4% | ▼-1.4% |
| Continuous Operations Profit Margin | 11.8% | ▲1.1% | ▼-1.5% |
| Net Profit Margin | 11.8% | ▲1.1% | ▼-1.5% |
| Bottom Line Profit Margin | 11.8% | ▲1.1% | ▼-1.5% |
| Current Ratio | 1.745 | ▼-0.099 | ▼-0.150 |
| Quick Ratio | 1.244 | ▼-0.086 | ▼-0.179 |
| Solvency Ratio | 0.208 | ▼-0.007 | ▼-0.053 |
| Cash Ratio | 0.244 | ▲0.038 | ▼-0.212 |
| Price To Earnings Ratio | 34.947 | ▼-13.989 | ▼-4.590 |
| Price To Earnings Growth Ratio | 2.505 | ▲4.747 | ▼-0.010 |
| Forward Price To Earnings Growth Ratio | 2.505 | ▲4.747 | ▼-0.010 |
| Price To Earnings Diluted Ratio | 34.947 | ▼-13.989 | ▼-4.590 |
| Price To Earnings Diluted Growth Ratio | 2.505 | ▲4.747 | ▼-0.010 |
| Price To Book Ratio | 3.146 | ▼-0.942 | ▼-1.589 |
| Price To Sales Ratio | 4.103 | ▼-1.098 | ▼-1.105 |
| Price To Free Cash Flow Ratio | 218.045 | ▲254.433 | ▲140.099 |
| Price To Operating Cash Flow Ratio | 17.013 | ▼-19.847 | ▼-22.635 |
| Debt To Assets Ratio | 0.185 | ▲0.001 | ▲0.012 |
| Debt To Equity Ratio | 0.317 | ▲0.011 | ▲0.020 |
| Debt To Capital Ratio | 0.241 | ▲0.007 | ▲0.013 |
| Long Term Debt To Capital Ratio | 0.185 | ▲0.007 | ▲0.018 |
| Financial Leverage Ratio | 1.711 | ▲0.053 | ▲0.001 |
| Working Capital Turnover Ratio | 2.843 | ▼-0.356 | ▲0.076 |
| Operating Cash Flow Ratio | 0.513 | ▲0.187 | ▲0.185 |
| Operating Cash Flow Sales Ratio | 0.241 | ▲0.100 | ▲0.093 |
| Free Cash Flow Operating Cash Flow Ratio | 0.078 | ▲1.091 | ▲1.145 |
| Debt Service Coverage Ratio | 1.681 | ▼-0.125 | ▼-0.891 |
| Interest Coverage Ratio | 8.396 | ▼-15.080 | ▼-23.720 |
| Short Term Operating Cash Flow Coverage Ratio | 2.258 | ▲0.800 | ▲0.323 |
| Operating Cash Flow Coverage Ratio | 0.584 | ▲0.221 | ▲0.138 |
| Capital Expenditure Coverage Ratio | 1.085 | ▲0.588 | ▲0.400 |
| Dividend Paid And Capex Coverage Ratio | 1.027 | ▲0.552 | ▲0.386 |
| Dividend Payout Ratio | 0.105 | ▼-0.017 | ▲0.005 |
| Enterprise Value Multiple | 17.381 | ▼-7.125 | ▼-3.956 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $4.67B | $5.74B | $6.54B | $4.44B | $5.23B | |
| Enterprise value | $5.02B | $6.07B | $6.87B | $4.43B | $5.06B | |
| EV / Sales | 4.40x | 5.50x | 6.33x | 4.50x | 6.00x | |
| EV / Op. cash flow | 18.25x | 38.98x | 65.28x | 42.90x | 37.94x | |
| EV / Free cash flow | 233.91x | -38.48x | -20.40x | -31.70x | 251.00x | |
| EV / EBITDA | 17.38x | 24.51x | 25.22x | 17.29x | 22.29x | |
| Net debt / EBITDA | 1.18x | 1.33x | 1.20x | -0.04x | -0.73x | |
| Current ratio | 1.75x | 1.84x | 1.50x | 1.83x | 2.56x | |
| Income quality | 2.05x | 0.97x | 0.56x | 0.55x | 0.81x | |
| Graham number | $8 | $7 | $7 | $7 | $6 | |
| Graham net-net | -$1 | -$1 | -$1 | -$0 | $1 | |
| Tax burden | 73.9% | 73.5% | 76.8% | 76.1% | 81.1% | |
| Interest burden | 89.3% | 95.9% | 97.8% | 97.9% | 97.1% | |
| Working capital | $398.8M | $402.6M | $287.5M | $383.3M | $527.3M | |
| Invested capital | $1.89B | $1.75B | $1.42B | $1.12B | $1.02B | |
| Return on assets | 5.3% | 5.1% | 7.0% | 8.6% | 9.5% | |
| Operating ROA | 7.5% | 7.3% | 10.8% | 12.5% | 13.6% | |
| Return on tangible assets | 5.5% | 5.2% | 7.3% | 9.0% | 10.0% | |
| Return on equity | 9.0% | 8.4% | 12.9% | 14.3% | 16.0% | |
| Return on invested capital | 6.4% | 6.0% | 9.4% | 11.6% | 11.7% | |
| Return on capital employed | 9.1% | 8.7% | 13.4% | 16.1% | 15.0% | |
| Earnings yield | 2.9% | 2.1% | 2.2% | 3.2% | 2.6% | |
| Free cash flow yield | 0.5% | -2.7% | -5.1% | -3.1% | 0.4% | |
| Capex / Op. cash flow | 92.2% | 201.3% | 420.0% | 235.3% | 84.9% | |
| Capex / Depreciation | 302.0% | 388.8% | 563.1% | 375.1% | 200.7% | |
| Capex / Sales | 22.2% | 28.4% | 40.7% | 24.7% | 13.4% | |
| SG&A / Sales | 10.8% | 10.7% | 10.5% | 11.4% | 9.8% | |
| R&D / Sales | 2.1% | 2.9% | 3.3% | 3.5% | 3.5% | |
| Stock comp / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Intangibles / Total assets | 3.4% | 3.6% | 3.9% | 4.8% | 5.6% | |
| Days sales outstanding | 174d | 175d | 176d | 137d | 120d | |
| Days payables outstanding | 119d | 105d | 136d | 132d | 104d | |
| Operating cycle | 295d | 287d | 301d | 254d | 214d | |
| Cash conversion cycle | 176d | 182d | 165d | 123d | 110d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▼-18.6%EV / Sales ▼-20.0%EV / EBITDA ▼-29.1%EV / Op. cash flow ▼-20.732Earnings yield ▲+0.008Graham number ▲+0.691
Profitability
Return on equity ▲+0.007Return on assets ▲+0.002Return on invested capital ▲+0.003Return on capital employed ▲+0.004Operating ROA ▲+0.002Income quality ▲+1.074Tax burden ▲+0.005
Efficiency
Days sales outstanding ▼-1.509Days payables outstanding ▲+13.544Operating cycle ▲+7.781Cash conversion cycle ▼-5.763Capex / Sales ▼-0.062R&D / Sales ▼-0.007
Balance-sheet strength
Current ratio ▼-0.099Net debt / EBITDA ▼-0.156Working capital ▼-3818816.000Invested capital ▲+138535734.000Intangibles / Total assets ▼-0.002
Change over 5 years
Valuation
Market cap ▼-10.5%EV / Sales ▼-26.6%EV / EBITDA ▼-22.0%EV / Op. cash flow ▼-19.692Earnings yield ▲+0.003Graham number ▲+1.734
Profitability
Return on equity ▼-0.069Return on assets ▼-0.042Return on invested capital ▼-0.054Return on capital employed ▼-0.059Operating ROA ▼-0.061Income quality ▲+1.241Tax burden ▼-0.071
Efficiency
Days sales outstanding ▲+53.249Days payables outstanding ▲+14.753Operating cycle ▲+80.224Cash conversion cycle ▲+65.471Capex / Sales ▲+0.088R&D / Sales ▼-0.014
Balance-sheet strength
Current ratio ▼-0.813Net debt / EBITDA ▲+1.914Working capital ▼-128516816.000Invested capital ▲+866970734.000Intangibles / Total assets ▼-0.022
Employee count
Peer market caps
Congressional trades
No congressional trade data synced.
Recent news
- 2026-08-11 Stevanato Group Q2 Earnings Call Highlights Stevanato Group (NYSE: STVN) reported second-quarter 2026 revenue growth of 8% as demand for higher-value drug containment and delivery products helped lift profitability, while the company updated its full-year outlook to reflect the divestiture of its California-based Balda C. Brewer subsidiary. Revenue for the quarter reached €302 million, up 8% both on a reported and constant-currency
- 2026-08-09 Stevanato Group Q2 Earnings Call Highlights Stevanato Group NYSE: STVN reported second-quarter 2026 revenue growth of 8% as demand for higher-value drug containment and delivery products helped lift profitability, while the company updated its full-year outlook to reflect the divestiture of its California-based Balda C. Brewer subsidiary.
- 2026-08-05 Is Stevanato (STVN) a Solid Growth Stock? 3 Reasons to Think "Yes" Stevanato (STVN) is well positioned to outperform the market, as it exhibits above-average growth in financials.
- 2026-08-04 Stevanato Group S.p.A. (STVN) Q2 2026 Earnings Call Transcript Stevanato Group S.p.A. (STVN) Q2 2026 Earnings Call Transcript
- 2026-08-04 Stevanato Group (STVN) Q2 Earnings Top Estimates Stevanato Group (STVN) came out with quarterly earnings of $0.16 per share, beating the Zacks Consensus Estimate of $0.15 per share. This compares to earnings of $0.12 per share a year ago.
- 2026-08-04 Stevanato Group Delivers 8% Revenue Growth for the Second Quarter of Fiscal 2026 PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced its financial results for the second quarter of 2026. Second Quarter of 2026 Highlights (comparisons to prior-year period) Revenue increased 8% to €302.0 million, with high-value solutions representing 45% of total revenue. Gross profit margin increase.
- 2026-07-30 Liraglutide Combination Products Incorporating Stevanato Group''s Alina® Pen Injector Received Marketing Authorizations in Multiple European Countries PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery and diagnostic solutions for the pharmaceutical, biotechnology and life sciences industries, today announced that liraglutide-based combination products incorporating Stevanato Group''s proprietary Alina® pen injector platform have received marketing authorizations in Europe. The authorizations relate to finished combination products held by the respective Mark.
- 2026-07-21 Stevanato Group to Report Second Quarter 2026 Financial Results on August 4, 2026 PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will issue financial results for the second quarter of 2026 on Tuesday, August 4, 2026, at 6:30 a.m. (EDT). Conference call and webcast: The Company will host a conference call and webcast at 8:30 a.m. (EDT) on Tuesday, August 4, 2026, to discu.
- 2026-06-11 Stevanato: HVS Momentum Overshadows Engineering Weakness, Offering Compelling Upside Stevanato Group is reiterated as a Buy, driven by robust Q1 results and a compelling long-term growth trajectory. The High-Value Solutions segment accelerated, now comprising 47% of sales, fueled by broad biologics and injectable therapies demand. Management attributed the slowdown in the Engineering segment to project timing and order delays rather than competitive pressure or deteriorating demand. Importantly, segment profitability improved despite lower volumes.
- 2026-06-09 2 Dirt Cheap Healthcare Stocks to Buy With $1,000 Right Now The shares of both stocks are down so far this year. Stevanato is benefiting from the need for GLP-1 injectables.